uniQure N.V. (QURE)

NL — Healthcare Sector
Peers: VRDN  GPCR  EWTX  OCUL  GLPG  VERA  NUVB  CLDX  MESO  ABCL 

Automate Your Wheel Strategy on QURE

With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol QURE
  • Rev/Share 0.2692
  • Book/Share 3.9091
  • PB 6.2585
  • Debt/Equity 0.2892
  • CurrentRatio 7.117
  • ROIC -0.2274

 

  • MktCap 1507136967.0
  • FreeCF/Share -2.6252
  • PFCF -9.8109
  • PE -6.0881
  • Debt/Assets 0.0745
  • DivYield 0
  • ROE -3.7373

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation QURE Wolfe Research -- Peer Perform -- -- Feb. 24, 2026
Initiation QURE Barclays -- Equal Weight -- $31 Jan. 28, 2026
Downgrade QURE William Blair Outperform Market Perform -- -- Nov. 4, 2025
Upgrade QURE Mizuho Neutral Outperform -- $30 Aug. 14, 2025
Resumed QURE Chardan Capital Markets -- Buy -- $38 April 1, 2025
Upgrade QURE Raymond James Outperform Strong Buy -- -- Dec. 10, 2024
Resumed QURE Raymond James -- Outperform -- $20 Oct. 10, 2024

News

NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
QURE
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral

PHILADELPHIA, Feb. 23, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period").

Read More
image for news NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
uniQure to Announce 2025 Financial Results
QURE
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral

~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~ ~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~

Read More
image for news uniQure to Announce 2025 Financial Results
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
QURE
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read More
image for news QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
QURE
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read More
image for news uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
QURE
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral

NEW YORK, Feb. 23, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period").

Read More
image for news QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
QURE
Published: February 22, 2026 by: Newsfile Corp
Sentiment: Neutral

New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.

Read More
image for news ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
QURE
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral

LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read More
image for news QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
QURE
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.

Read More
image for news uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
QURE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
QURE
Published: February 20, 2026 by: PRNewsWire
Sentiment: Neutral

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In uniQure To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V.

Read More
image for news QURE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
QURE
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral

New class action for uniQure (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Apr. 13, 2026.

Read More
image for news Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors
QURE
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral

LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises UniQure N.V., (“uniQure” or the "Company") (NASDAQ: QURE) investors of a class action on behalf of investors that bought securities between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). uniQure investors have until April 13, 2026 to file a lead plaintiff motion.

Read More
image for news Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors
QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
QURE
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options

Read More
image for news QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
QURE
Published: February 18, 2026 by: Newsfile Corp
Sentiment: Neutral

Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period").

Read More
image for news UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
QURE
Published: February 17, 2026 by: PRNewsWire
Sentiment: Neutral

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period").

Read More
image for news QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
Class Action Announcement for uniQure N.V. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against uniQure N.V.
QURE
Published: February 16, 2026 by: GlobeNewsWire
Sentiment: Neutral

RADNOR, Pa., Feb. 16, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). This action, captioned Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed in the United States District Court for the Southern District of New York.

Read More
image for news Class Action Announcement for uniQure N.V. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against uniQure N.V.
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
QURE
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral

LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read More
image for news QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
ATTENTION NASDAQ: QURE INVESTORS: Contact Berger Montague About an uniQure N.V. Class Action Lawsuit
QURE
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA, Feb. 13, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the “Class Period”).

Read More
image for news ATTENTION NASDAQ: QURE INVESTORS: Contact Berger Montague About an uniQure N.V. Class Action Lawsuit
Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
QURE
Published: February 12, 2026 by: PRNewsWire
Sentiment: Neutral

RADNOR, Pa., Feb. 12, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V.

Read More
image for news Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE
QURE
Published: February 12, 2026 by: GlobeNewsWire
Sentiment: Neutral

NEW ORLEANS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company's shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Read More
image for news uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
QURE
Published: February 12, 2026 by: PRNewsWire
Sentiment: Neutral

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V.

Read More
image for news QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Berger Montague PC Investigating Claims on Behalf of Investors in uniQure N.V. (QURE) After Class Action Filing
QURE
Published: February 11, 2026 by: Newsfile Corp
Sentiment: Neutral

Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the "Class Period").

Read More
image for news Berger Montague PC Investigating Claims on Behalf of Investors in uniQure N.V. (QURE) After Class Action Filing
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
QURE
Published: February 11, 2026 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). uniQure is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that uniQure N.V. (NASDAQ: QURE.

Read More
image for news Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of uniQure N.V. (QURE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
QURE
Published: February 11, 2026 by: GlobeNewsWire
Sentiment: Neutral

ATLANTA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding uniQure's business, operations, and prospects, including allegations that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; and (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License …

Read More
image for news INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of uniQure N.V. (QURE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
QURE
Published: February 06, 2026 by: Benzinga
Sentiment: Positive

uniQure N.V. (NASDAQ: QURE) on Friday announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase 1/2a trial of AMT-191.

Read More
image for news Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral

RADNOR, Pa., Jan. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

Read More
image for news QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
EXAS, GH, NBIS, NTRA, QURE, STVN
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive

Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.

Read More
image for news Alger Small Cap Focus Fund Q4 2025 Portfolio Update
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE
Published: January 12, 2026 by: GlobeNewsWire
Sentiment: Neutral

RADNOR, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

Read More
image for news QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
uniQure: Now What?
QURE
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Neutral

uniQure faces a major setback as the FDA reversed its stance on using external controls for AMT-130's approval, delaying its BLA submission. QURE's pivotal Phase 1/2 trial showed 75% slowing in cUHDRS at 36 months, but regulatory uncertainty now overshadows these results. With $694M in cash, QURE can weather a prolonged regulatory process, but AMT-130's near-term value is materially diminished.

Read More
image for news uniQure: Now What?
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE
Published: December 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

RADNOR, Pa., Dec. 30, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

Read More
image for news QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
QURE
Published: December 23, 2025 by: PRNewsWire
Sentiment: Neutral

RADNOR, Pa. , Dec. 23, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V.

Read More
image for news QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

About uniQure N.V. (QURE)

  • IPO Date 2014-02-05
  • Website https://www.uniqure.com
  • Industry Biotechnology
  • CEO Matthew Craig Kapusta
  • Employees 209

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.